Announcing the Essential Eye Cancer Podcast Page with Dr. Paul Finger! Dr. Finger has been working hard to give you this latest addition to the New York Eye Cancer website. For those of you who are auditory learners, these new Podcasts are where you can find your questions answered regarding Dr. Finger’s treatments, techniques and medical suggestions. Dr. Finger is an internationally recognized eye cancer specialist who offers excellence in ophthalmic oncology care and this information reflects his research, teaching, and experience caring for patients over the last 35 years.He has authored over 300 scientific articles, invented new methods for eye cancer diagnosis and treatment and always strives for excellence in his patient’s care.
The first PodCast posted on the page is about Dr. Finger’s anti-VEGF therapy. In 2006, Dr. Finger was the first to find that anti-VEGF intraocular injections can suppress radiation damage to the eye and thus save vision. However, like most medications for chronic disease, these drugs are typically given every 4-6 weeks! Click here to listen on Apple Podcasts! Other major podcast links are also available on our Podcast page. To read along, you can also open our brochure page to find the anti-VEGF brochures or click here. Following the debut of this first podcast, other topics will be posted to the podcast page every Monday. Be sure to check back each week to listen to a new podcast!
Dr. Paul Finger of the New York Eye Cancer Center is consistently rated among the best doctors in the greater New York City region.
As of 2023, Dr. Finger has appeared on the Castle Connolly list of “Top Doctors” in the New York area for the 16th time since 2005. Castle Connolly Medical Ltd., a New York City research and information company, creates this list yearly by using an online database of more than 53,000 Castle Connolly Top Doctors® across the US. Of these 53,000 doctors, 7,400 are located in the New York area. You can view Dr. Finger’s profile page on the Castle Connolly website here.
New York Magazine annually publishes their own list of “Best Doctors,” and as of 2023 our very own Dr. Paul Finger has consistently made their list over the past 18 years. Castle Connolly gives New York Magazine a shortened version of this list, which it then uses to create its list of Best Doctors in New York. In spite of this select group limited to 1,390 doctors, Dr. Finger has maintained on the noble list as one of the best ophthalmologists for eight years running (as of 2023) Read more on the New York Magazine website about how they select doctors for the list.
Regarding the decision method, Castle Connolly interestingly conducts a peer-review survey. The firm believes that physicians and medical professionals are in the best position to pass judgement onto other physicians. These participating physicians are asked to nominate doctors who they believe are the “best” in their specialties, taking into consideration not only professional excellence and reputation, but also personal patient interaction. They choose the best well-rounded doctors who transcend required knowledge of their practice and instill trust in and show empathy to their patients. Doctors are not permitted to nominate themselves and all nominations are confidential. These licensed doctors vote online (castleconnolly.com/nominations) for the doctors they find to be exceedingly exceptional.
Other prestigious recognition includes his selection for America’s Most Honored Professionals 2019 – Top 1%, America’s Top Doctors for Cancer 2019, and New York Metro Area’s Top Doctors 2019. These same awards are given every year and Dr. Finger has repeatedly been given the “Best Doctor” award for each. This consistency points to the dedication and ambition that Dr. Finger possesses, driven daily by his desire to help – to cure sight and to save lives.
A more than well-deserved title for our exceedingly outstanding physician!
As you may have heard in our previous blog, the American Academy of Ophthalmology (AAO) 2017 Meeting in New Orleans, Louisiana was attended by noteworthy fellowship alumni from the Eye Cancer Foundation, as well as founder and executive director of the ECF, Dr. Paul T. Finger. Held from November 11th to 14th, AAO took place the day following the 2017 AAOOP Annual Meeting, where oral presentations were given by ECF Fellows Dr. Sonal Chaugule and Dr. Abhilasha Maheshwari.
Dr. Chagule spoke on her research regarding the efficiency of intravitreal steroids to treat radiation side-effects, while Dr. Maheshwari spoke on a 12-year study of patients treated with slotted plaque radiation therapy. To read more on AOOP 2017 presentations from these ECF fellows, click here.
At AAO 2017, hosted at the Ernest N. Morial Convention Center in New Orleans, Dr. Sonal Chaugule, Dr. Ekatrina Semenova, and Dr. Nicole Scripsema presented ECF-sponsored research conducted under the guidance of Dr. Paul T. Finger at the New York Eye Cancer Center and at New York Eye and Ear Infirmary.
Dr. Sonal, pictured below along Dr. Finger, presented two studies, the first titled “Regression patterns of Iris Melanoma after Palladium-103 Plaque Brachytherapy”. This study takes into account 50 iris melanoma patients who were closely evaluated following plaque brachytherapy with Palladium-103 as treatment. The results of this study underscored Palladium-103 as effective treatment for iris melanoma. After incisive evaluation, patients showed decreases in tumor size, tumor pigmentation, and more. These findings are particularly important to iris melanoma patients, who endure a rare condition in the already-rare family of cancers (iris melanoma patients are only 2-3% of eye cancer cases). To read more on this paper and its implications, click here.
Dr. Chaugule’s second presentation concerned her paper most-recently published in the Indian Journal of Opthalmology. Titled “Primary Topical Chemotherapy for Giant Ocular Surface Squamous Neoplasia”, this paper examines and reports the outcomes of using topical chemotherapy eye drops (such as 5-Flurouracil and/or Interferon alpha-2b) to treat giant ocular surface squamous neoplasia. The paper was featured in a past blog post — to read more on the study, which evaluated 10 patients with stage T3 tumors, click here.
Details from AAO do not stop here! Stay tuned for more exciting news on the work ECF Fellows make towards eye cancer research by keeping eyecancer.com in your bookmarks!
how can patients choose the best doctor without knowing their past performance?
In the age of the internet, when HealthGrades and RateMDs are ready to profile a physician with the push of a button, it is now easier than ever to browse for healthcare options. Five-star reviews remarking on wait times and a doctor’s beside manner, while certainly valuable, miss the most important question a patient would like to know: how capable is this doctor of delivering good health outcomes?
For eye cancer patients in particular, understanding where to receive the best possible treatment is paramount. With these patients in mind, The New York Eye Cancer Center is now the first practice of its kind to report patient outcomes on the web in a patient-accessible format. Click here to see our latest Results.
Understanding the Report
We have launched the Results page with reports on three common conditions treated at NYECC: choroidal melanoma, iris-ciliary body melanoma, and squamous conjunctival malignancy. Though Dr. Finger’s clinical practice and peer-reviewed outcomes span his 30 years of practice, this new method of reporting starts with patients treated after December 1, 2017 and will be updated weekly going forward.
For each disease, we report on:
– Patients Entered: The number of patients included in these results.
– Visual Acuity: The median visual acuity, or eye chart test score, after finishing treatment.
– Local Tumor Control: The percentage of patients whose tumors are successfully eliminated through treatment.
– Loss of Eye: The percentage of patients whose cases require enucleation, or the removal of the eye, in order to complete treatment.
– Metastases: The percentage of patients whose tumors spread to other organs after treatment.
– Average Follow Up: Number of years after treatment before additional treatments are required.
The data, located on our Results page and observable through an interactive table, reports on patients treated only by Dr. Finger. Patient data is strictly confidential, HIPPA-compliant and anonymous.
A Piece of the Puzzle
This trailblazing Results page is the next step in a multi-year initiative by Dr. Finger and his colleagues to empower patients and improve outcomes across the ocular oncology specialty.
While medical journals have provided a forum to publish and compare treatment techniques, medicine does not currently have a strong framework to compare overall physician performance in a quantitative, objective manner. In response, a group of eye cancer specialists including Dr. Finger have formed the “International Doctor Reported Outcomes (DRO) Initiative.” This initiative is developing a standardized way for doctors to report their results to the public and each other.
Comparing outcomes is a great way to find areas for improvement in medical practice. More importantly for each individual patient, DRO reporting is a clear way to address that essential question: what are the past results of the doctor who is about to treat me?
The DRO Initiative has been developed over the course of the last two Eye Cancer Working Day conferences, which gathered ocular oncologists from around the world. But identifying a need and making a plan are but a prelude to the achieving our goal: a world in which all medical centers routinely publish their results for the public.
The launch of our results page is the first step, and we encourage other centers to join us in this effort. The Eye Cancer Foundation will offer assistance to any center or solo practitioner in setting up a page akin to the new NYECC Results page.
Let’s hold ourselves accountable to our outcomes and empower patients to make their life-changing choice of eye cancer specialist based on visible results.
The New York Eye Cancer Center is dedicated to combining both science and technology with a human touch, offering a holistic approach to the diagnosis and treatment of eye cancer. The Founding Director, Dr. Paul T. Finger, aims to extend his streamlined medical approach to others with the focus of not only helping doctors work together, but also providing easy-to-understand information. This is very important for patients who feel overwhelmed by the scope of medical terminology and technology. Every day, swift strides are being made towards a brighter future for eye cancer patients all around the world.
Here at The NYECC, a series of videos have been made and published, ranging from lectures for training specialists, to videos for patients on what to expect throughout the stages of their care.
In this video, Dr. Finger timelines his 30+ year medical career. He discusses his pioneering of the Palladium-103 plaque procedure for intraocular tumors, imaging methods for many eye cancers and anti-VEGF therapy now used world-wide to suppress radiation complications, plus more.
"Very well treated by Dr. Finger. He explained everything I needed to know about my issue with detail and attention, putting me at ease and giving me confidence to handle this problem for the rest of my life.”
– N.N.
